SOM Biotech announces today that it will present in silico and in vitro results regarding Eravacycline for the treatment of SARS-CoV-2 during a virtual poster presentation at the IDWeek 2020.

The poster is entitled “Repurposing of Eravacycline for the Treatment of SARS-CoV-2 Infections”. It outlines pre-clinical data demonstrating that Eravacycline is a potent inhibitor of the SARS-CoV-2 3CL protease.

Eravacycline was identified using an AI-based screening technology (SOMAIPRO), that analyzed a database of clinically tested compounds in search of inhibitors of SARS-CoV-2 3CL protease, a viral protein essential for coronavirus infection and replication in host cells.

Covalent docking calculations demonstrated that Eravacycline establishes a covalent bond with Cys145 in the catalytic domain of the SARS-CoV-2 3CL protease. In vitro experiments confirmed inhibition of the protease with an IC50 in the low micromolar range. Eravacycline inhibits the infection of SARS-CoV-2 in VeroE6 cells and shows no toxicity when applied alone.

The studies also showed that Eravacycline inhibits the 3CL proteases of other related coronaviruses, such as SARS-CoV and MERS-CoV. Thus, the data suggest that the drug could be repositioned for the treatment of beta-coronaviruses infections.

“It is a pleasure to share our in vitro findings on Eravacycline for the treatment of SARS-CoV-2 and to target the hospitalized patients by the virus. The drug accumulates in the lung and has anti-inflammatory and antibacterial activity. Therefore, it may play an important role in treating COVID-19 infections, additionally to its inhibitory capacity for virus replication. We are planning a Phase 2 clinical trial to prove the efficacy of Eravacycline in hospitalized COVID-19 patients”, says Raul Insa, CEO of SOM Biotech.

Presentation details as follows:

Session Category: Posters

Session Title: COVID-19 treatment

Presenter: Núria Reig

Poster Board Number: 560 – Repurposing Eravacycline for the Treatment of SARS-CoV-2 Infections

Abstract Number: 910853

Location: webpage of congress.

IDWeek2020. SOM Biotech. Treatment of SARS-CoV-2

SUBCRIBE TO OUR NEWSLETTER

    Name*
    Email*


    I confirm that by completing this form I have used only personal data about myself and that they are true and up-to-date.
    SOM INNOVATION BIOTECH, S.A. is responsible for the processing of my personal data to manage the newsletter service requested through the form, as well as to track the receipt of these through tracking technologies. The Privacy Policy tells me how I can exercise my rights of access, rectification, deletion, limitation, portability and opposition.